| Outcome | Study Design |
Author, Year Study/Trial Name | Comparison (IG vs. CG) | Age | Followup | IG n/N (rate per 1,000 screened) | CG n/N (rate per 1,000 screened) | Effect (95% CI) |
|---|---|---|---|---|---|---|---|---|
| False-positive recall† | RCT |
Armaroli, 2022129 Proteus Donna‡ | DBT/DM vs. DM (round 1), DM vs. DM‡ (round 2) | 46 to 68 | First Round | 1,699/30,844 (55.1) | 1,943/43,022 (45.2) | RR: 1.22 (95% CI, 1.14 to 1.30)* |
| Second Round | 900/23,760 (37.9) | 1,286/33,534 (38.3) | RR: 0.99 (95% CI, 0.91 to 1.08)* | |||||
|
Pattacini, 2022160 RETomo§ | DBT/DM (round 1), DM (round 2) vs. DM | 45 to 69 | First Round | 410/13,356 (30.7) | 461/13,521 (34.1) | RR: 0.90 (95% CI, 0.79 to 1.00)* | ||
| Second Round | 403/12,733 (31.7) | 430/12,911 (33.3) | RR: 0.95 (95% CI, 0.83 to 1.09)* | |||||
|
Hofvind, 2021143 To-Be§ | DBT/sDM vs. DM (round 1), DBT/sDM (round 2) | 50 to 69 | First Round | 349/14,380 (24.3) | 484/14,369 (33.7) | RR: 0.72 (95% CI, 0.63 to 0.83)* | ||
| Second Round | 349/11,201 (31.2) | 340/11,105 (30.6) | RR: 1.02 (95% CI, 0.88 to 1.18)* | |||||
| NRSI |
Sprague, in press BCSC-in press | DBT vs. DM | 40 to 79 | First Round | NR (66) | NR (101) | Proportion difference: −34 (95% CI, −47 to −22)§ | |
| Second Round | NR (60) | NR (78) | Proportion difference: −18 (95% CI, −30 to −7)§ | |||||
| ≥Third round | NR (55) | NR (66) | Proportion difference: −11 (95% CI, −23 to 2)§ | |||||
|
Hovda, 2020144 OVVV|| | DBT/sDM vs. DM (round 1), DM vs. DM (round 2) | 50 to 69 | First Round | 905/37,185 (24.3) | 1,658/61,742 (26.9) | RR: 0.91 (95% CI, 0.84 to 0.98)* | ||
| Second Round | 518/26,474 (19.6) | 1,154/45,543 (25.3) | RR: 0.77 (95% CI, 0.70 to 0.86)* | |||||
| False-positive biopsy¶ | RCT |
Hofvind, 2021143 To-Be | DBT/sDM vs. DM (round 1), DBT/sDM (round 2) | 50 to 69 | First Round | 157/14,380 (10.9) | 184/14,369 (12.8) | RR: 0.85 (95% CI, 0.69 to 1.05)* |
| Second Round | 157/11,201 (14.0) | 157/11,105 (14.1) | RR: 0.99 (95% CI, 0.80 to 1.24)* | |||||
| NRSI |
Sprague, 2023 BCSC | DBT vs. DM | 40 to 79 | First Round | NR (10) | NR (13) | Proportion difference: −3 (95% CI, −5 to −2) | |
| Second Round | NR (8) | NR (10) | Proportion difference: −2 (95% CI, −4 to 0) | |||||
| ≥Third round | NR (8) | NR (8) | Proportion difference: −1 (95% CI, −3 to 1) |
Relative risk calculated from Ns.
Recalled for assessment without a finding of invasive cancer or DCIS.
Recalled for an assessment after double reading based on positive or suspicious screening result by either radiologist (without consensus or arbitration).
Adjusted for age, breast density, race and ethnicity, time since last mammogram, Breast Cancer Screening Consortium 5-year invasive breast cancer risk, benign biopsy history, family history of breast cancer, and examination year.
Recalled for an assessment (after double reading and arbitration) based on positive or suspicious screening results.
Underwent biopsy without a finding of invasive cancer or DCIS.
Abbreviations: CG=control group; CI=confidence interval; DBT=digital breast tomosynthesis; DM=digital mammography; IG=intervention group; NRSI=nonrandomized study of intervention; RCT=randomized controlled trial; RETomo=Reggio Emilia Tomosynthesis Trial; RR=relative risk; sDM=synthetic 2-view mammography; To-Be=Tomosynthesis Trial in Bergen; OVVV=Oslo-Vestfold-Vestre Viken
From: Chapter 3, Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.